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(ABCC5) confer resistance to the nucleoside
analogs cytarabine and troxacitabine, but not
gemcitabine
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and Godefridus J Peters1*Abstract
We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance
to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine. For this
purpose we used HEK293 and the transfected HEK/MRP4 (59-fold increased MRP4) or HEK/MRP5i (991-fold increased
MRP5) as model systems and tested the cells for drug sensitivity using a proliferation test. Drug accumulation was
performed by using radioactive Ara-C, and for GEM and troxacitabine with HPLC with tandem-MS or UV detection. At
4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine
(PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM. The inhibitors probenecid and indomethacin reversed
resistance. After 4-hr exposure ara-C-nucleotides were 2-3-fold lower in MRP4/5 cells, in which they decreased
more rapidly after washing with drug-free medium (DFM). Trocacitabine accumulation was similar in the 3 cell
lines, but after the DFM period troxacitabine decreased 2-4-fold faster in MRP4/5 cells. Troxacitabine-nucleotides
were about 25% lower in MRP4/5 cells and decreased rapidly in MRP4, but not in MRP5 cells. Accumulation of
GEM-nucleotides was higher in the MRP4/5 cells. In conclusion: MRP4 and MRP5 overexpression confer resistance
to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and
troxacitabine-nucleotides in HEK/MRP4-5 cells.
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The ATP-binding cassette (ABC) transporters consist of
a family of integral membrane proteins capable of uni-
directional transport of a wide variety of compounds
across cell membranes. Part of the natural function is
protection against xenobiotics, by pumping them out of
the cell. This transport by ABC transporters occurs against
a concentration gradient made possible by ATP hydrolysis
(Borst and Elferink 2002). On the basis of sequence
homology and domain organization the ABC family is sub-
divided into seven subfamilies (ABCA-ABCG) (Gottesman
et al. 2002). The ABCC (MRP) subfamily consists of nine* Correspondence: gj.peters@vumc.nl
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in any medium, provided the original work is prelated transporters (ABCC1-6, ABCC10-12 or MRP1-9);
these MRP proteins have at least 2 hydrophobic trans-
membrane domains and 2 cytoplasmatic domains. The
MRP family is subdivided according to the presence or
absence of a third transmembrane domain; MRPs 1, 2,
3, 6 and 7 contain this third transmembrane domain,
while the other MRPs don’t contain this domain. The
presence of this third transmembrane domain is re-
sponsible for different substrate specificity between the
MRPs possessing and lacking this domain (Borst and
Elferink 2002; Deeley et al 2006; Gottesman et al. 2002;
Kruh and Belinsky 2003).
Next to their natural function, most MRP transporters
have been implicated in drug resistance, but they have a
wide range of different substrate specificities (Deeley et al
2006; Gottesman et al. 2002; Kruh and Belinsky 2003).an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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limited. The MRP transporters that don’t contain a third
transmembrane domain, MRP4 (ABCC4), MRP5 (ABCC5)
and MRP8 (ABCC11), are capable of transporting mono-
phosphorylated nucleoside analogs, which can confer
resistance to, amongst others, 6-mercaptopurine, 6-
thioguanine and PMEA for MRPs 4 and 5 (Fukuda and
Schuetz 2012; Reid et al 2003; Wijnholds et al 2000),
while MRP8 is also able to transport fluoropyrimidines
(Kruh and Belinsky 2003).
Cytarabine and Gemcitabine are deoxynucleoside an-
alogs frequently used in the treatment of solid (dFdC)
(Heinemann 2002; Hussain and James 2003; Ramalingam
and Belani 2008) and hematological cancers (Ara-C)
(Plunkett and Gandhi 1993; Momparler 2013). Troxacita-
bine is an experimental deoxynucleoside analog, which
has an unnatural L-orientation; causing differences in up-
take and metabolism compared to other deoxynucleoside
analogs (Grove et al 1995; Gourdeau et al 2001; Gumina
et al 2006) (Figure 1). Resistance to deoxynucleoside ana-
logs poses a limitation to the clinical efficacy in the treat-
ment of cancer, making the treatment less effective and
requiring higher doses with higher risks of side effects
(Lage 2008; Kruh 2003). Limited information is available
on the role of MRPs in drug resistance to nucleoside ana-
logs. MRP4 and MRP5 have been implicated in resistance
to thiopurines and phosphonates such as PMEA (Reid
et al 2003; Wielinga et al 2002; Schuetz et al 1999; Chen et
al 2001). MRP5 and MRP8 have also been shown to be in-
volved in antimetabolite resistance (Pratt et al 2005;
Guo et al 2003). The mechanism is based on efflux of
the somewhat polar phosphonate and of the monopho-
sphates of 6-mercaptopurine and 5-fluorouracil out of the
cell; in contrast the more polar di- and triphosphates are
not a substrate, similar to the efflux of methotrexate
monoglutamate compared to the higher glutamate forms
(Hooijberg et al 1999; De Wolf et al 2008). It was reported
that for some nucleosides such as clofarabine and gemci-
tabine another ABC transporter (ABCG2) might confer
resistance to a nucleoside analog, in which the nucleoside



































Figure 1 Structural formulae of deoxycytidine, gemcitabine, cytarabinMRP 4 and 5 have related structures and show a similar
ability to transport nucleotide analogs. However, gemcita-
bine is more effectively phosphorylated than Ara-C and
troxacitabine, but troxacitabine shows a different uptake
mechanism. Using HEK cells transfected with either MRP4
or MRP5, we investigated whether MRP4 and 5 were in-
volved in the efflux of nucleoside analogs from cancer cells.Materials and methods
Drugs
Cytarabine (Ara-C) was from Sigma-Aldrich (St. Louis, MO,
USA), gemcitabine (dFdC) was from Eli-Lilly (Indianapolis,
IN, USA), troxacitabine was from Shire BioChem (Laval,
Quebec, Canada), PMEA was a gift from Prof. J. Balzarini,
Rega Institute, Leuven, Belgium, tetrahydrouridine (THU)
was from Calbiochem (Merck, Darmstadt, Germany),
indomethacin and probenecid were from Sigma-Aldrich
(St. Louis, MO, USA). 3H-cytarabine was obtained from
Moravek (Brea, CA, USA). Rat monoclonal antibodies
against MRP4 and MRP5 were used to detect the ex-
pression of MRP4 and MRP5, respectively (Wielinga et al
2003; Lemos et al 2009). As secondary antibody a
horseradish peroxidase-conjugated rabbit-anti-rat antibody
(DakoCytomation, Glostrup, Denmark) was used (Lemos
et al 2009).Cell lines
For the experiments the HEK human embryonic kidney
cells transfected with MRP4 and MRP5i were used. The
doubling times of the cell lines were 19, 17 and 16 hr,
respectively. The cells were kindly provided by Dr. P.R.
Wielinga from the Netherlands Cancer Institute (Wielinga
et al 2003). Earlier experiments did not show differences
between the wild-type HEK and mock transfected cells.
The cell lines were cultured in DMEM medium with glu-
tamine (BioWhittaker, Verviers, Belgium), supplemented
with 10% fetal calf serum (Gibco, New York, NY, USA)
and 20 mM HEPES buffer (BioWhittaker).
Both HEK/MRP4 and HEK/MRP5i cells were character-


























e, troxacitabine and PMEA.
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described earlier by Lemos et al (2009).
Chemosensitivity assay
As chemosensitivity assay we used the SRB assay
(Keepers et al 1991) rather than a clonogenic assay. For
the present purpose, differences in chemosensitivity, we
earlier demonstrated that the SRB assay is an appropriate
assay (Keepers et al 1991; Pizao et al 1992; Ferreira et al
2000). Cells were transferred to 96 wells plates; on day one
a serial dilution of one drug was added to the cells. The
cells were incubated for 72 hours with drugs or for 4 hours
with drugs and 68 hours with drug free medium. The rela-
tive amount of cells at drug addition was determined by
fixing control wells at day 0 (drug addition) and processed
as described below. The other (treated and control) cells
were fixed after the incubation period, and washed and
stained with SRB. The stained proteins were measured at
492 nm with an automated spectrophotometric microplate
reader (Tecan, Salzburg, Austria); the measured optical
density correlates with the amount of cells at the moment
of fixing.
The data were plotted in a graph to give a growth in-
hibition curve, according to the guidelines as published
by the NCI (http://dtp.nci.nih.gov/branches/btb/ivclsp.html).
From this growth inhibition curve the IC50 value was
determined by interpolating at the 50% growth level.
Ara-C metabolism
Ara-C metabolism was investigated by a procedure de-
scribed earlier using 3H-Ara-C (Adema et al 2012). Shortly,
cells were harvested and resuspended in fresh medium at
5x106 cells/ml. Of this cell suspension 100 μl was used for
each experiment. To inhibit deamination by CDA, THU
was added at a final concentration of 100 μM (Yusa et al
1995), the drugs were added to reach a final concentration
of 8.7 μM for Ara-C (specific activity 1789 mCi/mmol).
The cells were incubated for 4 hours at 37°C. In order to
measure drug retention the drug-containing medium was
replaced after 4 hours and the cells were incubated for
2 hours in drug free medium. Thereafter the cells were
spun down (3000 g, 2 min, 4°C) and the medium was
stored as extracellular fraction at -20°C. The cells were
washed with cold PBS (12000 g, 1 min, 4°C). The cell
pellet was resuspended in 45 μl cold PBS and extracted
by addition of 5 μl perchloric acid (5 M) and chilled on
ice for 20 minutes. The supernatant containing the
cytosolic fraction was neutralized with 10 μl KH2PO4
(5 M) and stored as intracellular fraction at -20°C.
Of the extracellular and intracellular cytosolic samples
5 μl was spotted onto a plastic backed silica thin-layer
chromatography plate (Merck KgaA, Darmstadt, Germany).
The chromatography was performed with chloroform/
methanol (3:2 v/v) as a mobile phase. After separationthe spots were visualized with UV light and cut into separ-
ate scintillation vials, and radioactivity was eluted by over-
night incubation in methanol. The samples were measured
together with the perchloric acid pellet samples in an
LSC counter and quantified as disintegrations per minute
(dpm).
Accumulation of dFdCTP
Cells were treated with 25 μM of dFdC. The cells were
incubated for 4 hours and retention of the triphosphates
was investigated after 2 and 4 hours incubation in drug-
free medium. Thereafter the cell pellet was resuspended
in 150 μl ice-cold PBS and incubated for 20 minutes at
4°C with 40% trichloroacetic acid. After centrifugation
(10,000 g, 10 min, 4°C) the supernatant was treated with a
2-fold excess of trioctylamine/1,1,2-trichlorotrifluorethane
(1:4) and spun down (10,000 g, 1 min) and the aqueous
phase was stored at -20°C. For measurement of gemcita-
bine triphosphate (dFdCTP) these samples were analyzed
by HPLC on a Whatman Partisphere SAX column (GE
healthcare, Chalfont St. Giles, UK) using isocratic gradient
elution as described earlier (Ruiz van Haperen et al 1994;
Noordhuis et al 1996). The accumulation of dFdCTP was
expressed relative to the concentration of ATP.
Accumulation of Troxacitabine and its phosphates
Cells were treated with 10 μM troxacitabine and were
extracted similarly as described for dFdCTP. An aliquot
of the cell pellet was retained for protein determination.
For measurement of troxacitabine and its nucleotides,
the acid-precipitated aliquots of troxacitabine treated
samples were split, one for troxacitabine and the other
for the nucleotides. The latter aliquot was incubated with
ammonium bicarbonate and alkaline phosphatase at 37°C
for 2 hours. Thereafter the samples were cleaned of alka-
line phosphatase by the addition of ice-cold isopropyl al-
cohol. The supernatant was cleaned of inorganic content
by freeze drying and reconstituting in ethyl acetate. After
back extraction with water the aqueous layer was used for
LC-MS/MS analysis. Mass spectroscopic sensitivity and
analytical parameters of troxacitabine were established as
the molecular ion [M+H] + of 214.2 and a product ion of
112 amu corresponding to the nucleoside base, which is a
typical fragmentation pattern for nucleosides and nucleo-
side analogues (Honeywell et al 2007). Analysis of troxaci-
tabine and its nucleotides was performed similarly to that
described earlier for deoxynucleoside analogs (Sigmond
et al 2009; Bijnsdorp et al 2011). Chromatography con-
sisted of a gradient system using 100% aqueous formic
acid (0.1%) as buffer A and 40% aqueous formic acid
(0.1%)/60% methanol for buffer B. The gradient consisted
of an initial 2 minute hold at 96% buffer A followed by an
increase to 100% buffer B over 10 minutes with a Phe-
nomenex 100 × 2.0 mm ODS3, 3 μm column maintained
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determines the concentration in ng/ml of the aliquot
taken. After taking dilution factors into consideration, the
number of moles of troxacitabine is determined for each
cell pellet before and after incubation with alkaline phos-
phatase. The first measurement is the free troxacitabine
and the difference between the two measurements is the
total phosphorylation product of troxacitabine. Each result
is adjusted for the either the protein content of the cell
pellet or the cell count of the original pellet.
Statistics
Significance of differences between wild-type and MRP4
or MRP5 transfected cells, and of different treatments,
was evaluated with Student’s t-test using the options pro-
vided in either the Excel or Prism Graphpad program. De-
pending on the research question, testing was paired or
unpaired. Cut-off for significance was set at p < 0.05.
Results
Transfected HEK cells were characterized by Western blot-
ting by using specific antibodies against MRP4 and MRP5
(Lemos et al 2009). Both variants had a high overexpres-
sion of either MRP4 or MRP5. Due to the transient nature
of transfections, the cells had to be challenged regularly
and were checked for their expression (Figure 2). However,
using this procedure expression of MRP4 and MRP5 in
these cell lines was stable throughout the course of each
experiment and similarly high between experiments.
Earlier we also demonstrated that expression of nucleoside
activating enzymes such as deoxycytidine kinase does not
change during this period (data not shown).
HEK cells, wild-type and transfected variants, were ex-
posed to the drugs for 4 and 72 hours (Figure 3). Previously
we have shown for several deoxynucleoside analogs that
cells were less sensitive at a short exposure (Ruiz van
Haperen et al 1994). Although cross-membrane trans-




Figure 2 Expression of MRP4 and MRP5 in the parent HEK cells and t
loading of proteins had to be decreased to prevent overloading.accumulation is much slower and depends on characteris-
tics of each cell line and is different for each nucleoside
analog (Adema et al 2012; Yusa et al 1995; Ruiz van
Haperen et al 1994; Plunkett and Gandhi 1993). Hence,
on the short term (less than 4 hr) this different metabolism
leads to a low accumulation of Ara-C triphosphate and a
much higher accumulation of gemcitabine-triphosphate;
for Ara-C at 4 hr this also results in a relatively large pro-
portion of monophosphates (Ruiz van Haperen et al 1994;
Noordhuis et al 1996). These are relative good substrates
for efflux pumps in contrast to the triphosphates (Reid
et al 2003; Wielinga et al 2002; Pratt et al 2005). There-
fore we reasoned that a role for MRP4 and MRP5 would
be more pronounced at a short incubation as was also
found for antifolates (Hooijberg et al 1999). The 4/72 hr
ratio of IC50 values was higher in MRP4 and MRP5 cells
compared to the wild type for troxacitabine (5.9 and 7.1
vs 3.3) and Ara-C (4.3 and 4.4 vs 3.3), but not for dFdC
(Table 1).
Exposure of the MRP 4 and 5 overexpressing cell lines
to Ara-C, dFdC, troxacitabine and PMEA showed a dif-
ferential resistance compared to the parental cell line both
at 4 compared to 72 hours exposure (Table 1). PMEA was
used as a positive control since this compound is known
to be a substrate for MRP4 and MRP5 (Reid et al 2003).
The modest 4-fold resistance was within the expected
range. However, the highest resistance, although still mod-
est, was observed for troxacitabine in the HEK/MRP4 cell
line, while no real resistance was observed in the HEK/
MRP5 cell line. Resistance to Ara-C was observed in both
the overexpressing cell lines. The effects at 72 hours ex-
posure were either absent (dFdC) or lower. No resistance
was seen for dFdC; for troxacitabine just a low1.4-fold in
MRP4 cells and for Ara-C an equally low 2- and 1.6-fold
in MRP4 and MRP5 cells, respectively.
For both Ara-C and troxacitabine we investigated whether
inhibition of MRP4 or MRP5 would increase sensitivity. The
inhibitors indomethacin and probenecid increased sensitivityMRP5
β-actin43 KDa
190 KDa
he resistant variants HEK/MRP4 and HEK/MRP5i. For MRP5i cells
Figure 3 Representative growth curves for troxacitabine showing the different sensitivity at long (72 hr) and short (4 hr) term exposure.
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(Figure 4a); inhibition of MRP5 with indomethacin only
increased the sensitivity to Ara-C (Figure 4b). Although
these transporters are not specific, they would only in-
hibit MRP4 or MRP5, since that is the only detectable
transporter in the transfected cells. Moreover, in wild-
type cells neither indomethacin or probenecid affected
the sensitivity of either drugs, excluding the possibility
that inhibition of another transporter might be respon-
sible for the observed effect in the transfected cells.
To further elucidate the mechanisms explaining the
resistance we investigated the accumulation and reten-
tion of troxacitabine, Ara-C, dFdC and their respective
phosphorylated forms. Accumulation of phosphorylatedtroxacitabine was lower in both the HEK/MRP4 and
HEK/MRP5i cell lines compared to the wild-type HEK
cells (Figure 5a), this decrease was most pronounced in
the MRP4 cell line after 4 hours exposure to troxacita-
bine and after 2 hours incubation in drug-free medium.
Next to the phosphorylated troxacitabine, the free trox-
acitabine also showed a markedly decreased retention
in both the HEK/MRP4 and the HEK/MRP5i cell lines
(Figure 5b), which was most pronounced in the HEK/
MRP4 cell line. None of the nucleotides was detectable
outside the cells; apparently in case they are effluxed their
concentration would be so far diluted that it would be even
below the detection limit of our sensitive LC-MS-MS assay
(troxacitabine) or radioactivity (ara-C).
Table 1 Sensitivity of HEK cells to troxacitabine, Ara-C and gemcitabine in comparison to PMEA
Time HEK HEK/MRP4 RF HEK/MRP5i RF
Troxacitabine 4 h 11.0 ± 2.6 29.0 ± 4.0** 2.6 14.2 ± 3.0+ 1.3
72 h 3.3 ± 0.2 5.0 ± 0.8 1.5 2.0 ± 0.1+ 0.61
Ratio IC50 4/72 h 3.3 5.9 7.1
Ara-C 4 h 8.3 ± 0.6 23.3 ± 4.4* 2.8 17.7 ± 1.5** 2.1
72 h 2.5 ± 1.5 5.4 ± 1.6 2.2 4.0 ± 1.5 1.6
Ratio IC50 4/72 h 3.3 4.3 4.4
Gemcitabine 4 h 0.43 ± 0.08 0.60 ± 0.12 1.4 0.50 ± 0.06 1.2
72 h 0.046 ± 0.006 0.061 ± 0.008 1.3 0.07 ± 0.01 1.5
Ratio IC50 4/72 h 9.3 10.0 7.1
PMEA 4 h 600 ± 40 2500 ± 100** 4.2 2567 ± 550** 4.3
Value (in μM) are means ± SE of 3-4 separate experiments.
Statistical difference: significantly different from wild-type cells (+,P < 0.05; *,P<0.02; **,P < 0.01).
HEK/MRP5i more sensitive than HEK/MRP4: +,P < 0.05. RF, resistance factor, ratio between IC50 of MRP4 or MRP5 cells divided by that of HEK wild type cells.
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were lower in both the HEK/MRP4 and HEK/MRP5i
cell lines compared to the wild-type HEK cells (Figure 6),
however the decrease was most pronounced in the HEK/
MRP4. The differences in both Ara-C and phosphorylated
Ara-C were larger after incubation in drug-free medium.
In all three cell lines the concentration of Ara-C decreased
about 10-fold during incubation in drug-free medium, but
that of Ara-C nucleotide only 5-fold in the wild-type.
However, in both MRP4 and MRP5 cells remaining nucle-
otides were much lower than in the wild-type cells.
The accumulation and retention of dFdCTP showed a
completely different pattern compared to Ara-C and trox-
acitabine. First, after 4 hours exposure dFdCTP accumula-
tion was higher in the MRP4 and MRP5 cells compared
to the wild-type HEK (Figure 7). Furthermore dFdCTP
accumulation continued to increase upon withdrawal of
gemcitabine both after exposure to 25 or 50 μM gemcita-
bine (data not shown).
Discussion
In this study we have shown that overexpression of MRP4
or 5 confers resistance to the anti-cancer nucleoside
analog cytarabine, due to efflux of Ara-CMP mediated
by MRPs 4 or 5. The L-orientated nucleoside analog trox-
acitabine was a substrate for both MRP4 and MRP5, as
well as its mono-phosphate appeared to be. On the other
hand no evidence was obtained that the nucleoside analog
gemcitabine or its nucleotides are a substrate for either
MRP 4 or 5.
Most MRP transporters have been implicated in cellular
drug resistance, but their potential role in clinical drug re-
sistance has still not been clarified. They have a wide range
of substrate specificities (Deeley et al 2006; Kruh and
Belinsky 2003). It was previously shown that various
anti-viral mono-phosphorylated nucleoside analogs are sub-
strates to MRPs that don’t contain a third transmembranedomain (Reid et al 2003; Wielinga et al 2002; Schuetz et al
1999; Chen et al 2001; Pratt et al 2005; Guo et al 2003).
The MRPs that don’t contain this third transmembrane do-
main are MRP 4, 5 and 8. As a positive control we included
PMEA, which indeed showed a resistance in the MRP4 and
MRP5 cells, similar to that published earlier (Reid et al
2003; Fukuda and Schuetz 2012). Also the lack of a differ-
ence for ara-C and gemcitabine at a long exposure (72 hr)
was shown earlier (Reid et al 2003), but shorter exposures
were not tested. Resistance to Ara-C and troxacitabine were
in the same range, indicating a similar mechanism of drug
efflux.
The data show that Ara-CMP, troxacitabine monopho-
sphate and troxacitabine are substrates for MRP4. The
sensitivity experiments showed the largest extent of re-
sistance for these analogs in the MRP4 transfected cell
line, while this resistance was reversible by the inhibition
of MRP4. The reduction in accumulation and retention
of both the unphosphorylated and phosphorylated analogs
underlined these results. Cytarabine monophosphate may
also be a substrate for MRP5, indicated by the decreased
sensitivity in the transfected cell line, the decrease in accu-
mulation and retention of both the unphosphorylated and
phosphorylated cytarabine.
Literature data on resistance to deoxynucleoside ana-
logs due to increased efflux is scarce. It was shown that
ABCG2 (BCRP) might confer resistance to the deoxynu-
cleoside analogs clofarabine and gemcitabine (De Wolf
et al 2008), while MRP5 and MRP8 may confer resistance
to fluoropyrimidines by effluxing the mononucleotides
(Kruh and Belinsky 2003; Pratt et al 2005; Guo et al 2003;
Li et al 2011). A similar pattern was found for methotrex-
ate, for which a resistance was found for MRP1-5 and
BCRP (Hooijberg et al 1999; De Wolf et al 2008; Wielinga
et al 2005). A common denominator for all these resist-
ance patterns was the fact that all compounds need to



































Figure 4 Effect of the MRP4 and MRP5 inhibitors on sensitivity to troxacitabine (trox) and Ara-C in the HEK/MRP4 (a) and HEK/MRP5i
(b) cell lines. Values represent IC50 (μM) ± SEM after 4 hours exposure to drugs and inhibitor of at least 3 separate experiments. Thereafter cells
were cultured in drug-free medium and drug sensitivity was measured 68 hr thereafter with the SRB assay. The effect of indomethacin and
probenecid on troxacitabine sensitivity was significant compared to the control (no inhibitor) in HEK/MRP4 cells (*,p < 0.01); in HEK/MRP5i
cells only the effect of indomethacin was significant (+,p < 0.05) (paired t-test)
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substrate specificity was limited to the somewhat polar
phosphonate (PMEA), the mononucleotide (Clofarabine,
5-fluorouracil, 6-mercaptopurine) or the monoglutamate,
the least polar metabolite from these metabolite drugs.
Since the di- and triphosphate forms of nucleotides and
the polyglutamates derivatives of methotrexate (e.g. di to
penta glutamates), are much more polar they are poor
substrates for the MRP4 and MRP5 pumps. Only BCRP
was able to efflux some of the polyglutamates. Another
common denominater was that resistance was usually only
found at short exposure to the drugs, especially with drugs
which have a rapid metabolism to the nucleotides or poly-
glutamates, such as gemcitabine and tomudex, respect-
ively (Hooijberg et al 1999). Hence, only for troxacitabine
and ara-C a resistance was found, since these drugs arenot metabolized rapidly enough to form a triphosphate
after 4 hr. Another novel finding of our data is that
troxacitabine is also a substrate for MRP4, in contrast to
unphosphorylated Cytarabine or gemcitabine. This is
possibly because troxacitabine is more polar then cytar-
abine (Gourdeau et al 2001); another difference of the
L-nucleoside troxacitabine compared to other non-L
nucleoside analogs, is that is not a substrate for the hu-
man equilibrative nucleoside transporter (Gourdeau et al
2001). Another interesting finding of our data is that gem-
citabine is not a substrate for MRP4 or MRP5, probably
because it is converted to gemcitabine triphosphate too
rapidly to be effluxed (Fukuda and Schuetz 2012). This is
confirmed by the sensitivity, which is only marginally
decreased in the transfected cell lines. It can however, not



























































































































Figure 5 Accumulation and retention of free troxacitabine (trox) (a) and troxacitabine-nucleotides (b) in the HEK, HEK/MRP4 (HEK/4)
and HEK/MRP5i (HEK/5) cell lines. T = 4: 4 hours exposure to 10 μM troxacitabine, T = 4 + 2: 4 hours exposure to troxacitabine followed by
2 hours drug-free medium. Values represent fmol/μg protein ± SEM of 3 separate experiments. For free troxacitabine the effect of drug-free medium
was significant (*,p < 0.01) (paired t test). Accumulation was measured in the absence of indomethacin or probenecid.
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phosphate might be a substrate. However, the transfected
HEK cells are already relatively poor gemcitabine metabo-
lizers compared to other cell lines tested in our laboratory
for gemcitabine (Ruiz van Haperen et al 1994; Noordhuis
et al 1996). Although the mechanisms were not elucidated
some evidence was presented that gemcitabine and Ara-C
resistance might be related to MRP7 overexpression
(Ikeda et al 2011; Hopper-Borge et al 2009). For Ara-C
it was shown that this was due to an increased efflux of
Ara-CMP (Hopper-Borge et al 2009).
Since MRP4 and MRP5 are relatively wide distributed
(Hooijberg et al 2006; Fukuda and Schuetz 2012), our
findings may have consequences for the application of
these drugs in the clinic, i.e. how can a potential resistance
mechanism be bypassed? In this paper we focused on the
role of MRP4 and MRP5 using two syngenic HEK celllines, instead of using cell lines with intrinsic or acquired
resistance to either ara-C, troxacitabine or gemcitabine. In
the latter models one might have to deal with other mech-
anisms, while transfected, syngeneic cell lines are clean in
this aspect. Of course other mechanisms in the complex
setting of a patient, cannot be excluded. These include
among others, limited transport, decreased phosphoryl-
ation and alterations in the target (Plunkett and Gandhi
1993). For nucleoside analogs such as Ara-C and gem-
citabine it has been demonstrated earlier (Plunkett &
Gandhi 1993; Momparler 2013; Ruiz van Haperen et al
1994; Noordhuis et al 1996) that their effect is schedule
dependent; at long incubation their sensitivity is increased
compared to a short exposure. This is due to a rela-
tively slow formation of the active nucleotides. There-
fore administration schedules for Ara-C are relatively
























Figure 7 Accumulation and retention of dFdCTP in the HEK, HEK/MRP4 and HEK/MRP5i cell lines. T = 4: 4 hours exposure to 25 μM dFdC,
T = 4 + 2: 4 hours exposure to dFdC followed by 2 hours drug-free medium. Values represent dFdCTP/ATP ratio ± SEM of 3 separate experiments.
The accumulation of dFdCTP was significantly higher in HEK/MRP5i cells compared to wild type HEK cells (+, p < 0.05) (unpaired t test). Accumulation


































Figure 6 Accumulation and retention of free Ara-C (a) and phosphorylated Ara-C (Ara-CxP) (b) in the HEK, HEK/MRP4 and HEK/MRP5i
cell lines. T = 4: 4 hours exposure to 10 μM Ara-C, T = 4 + 2: 4 hours exposure to Ara-C followed by 2 hours drug-free medium. Values represent
DPM ± SEM of 3 separate experiments. For both free Ara-C and Ara-CxP the effect of drug-free medium was significant (*, p < 0.01) (paired t test).
For free Ara-C the accumulation was significantly lower in HEK/MRP4 and HEK/MRP5i cells compared to wild-type HEK cells (+, p < 0.05) (unpaired
t-test), for the Ara-CxP this only holds for HEK/MRP4 cells. Accumulation was measured in the absence of indomethacin or probenecid.
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that the standard 30 min infusion. Indeed a 24-hr infu-
sion with gemcitabine showed the best antitumor effect
in mice (Veerman et al 1996). Plunkett et al suggested
giving gemcitabine in a longer infusion to optimize
gemcitabine phosphorylation; the so-called fixed rate
infusion of 10 mg/min/m2 seemed to give a better effect in
a phase 2 study, although the results were not confirmed
in a randomized phase 3 (Tempero et al 2003; Poplin et al
2009). In case gemcitabine would be a substrate for not
only MRP7 but also other ABC transporters, such a
schedule would serve two purposes, a prolonged period
of gemcitabine exposure would increase gemcitabine
phosphorylation, while the length of exposure would also
prevent efflux of gemcitabine-MP. Alternatively, a similar
effect was observed with a gemcitabine prodrug, CP-4126
(now CO1.01), which showed a prolonged retention in the
cells, resembling a long exposure (Adema et al 2012).
In this paper we focused on the use of specific model
systems (wild type cells transfected MRP4 or MRP5) in-
stead of cancer cell lines with a naturally high expression
of any of the MRPs, including MRP4, 5 or 8. In cancer
cells another potential resistance mechanism would eas-
ily overrule a MRP mediated resistance, which did not
happen in our models. Also the use of primary cancer
cells would give the same problem, since they are almost
by definition characterized by resistance due to mul-
tiple alterations in the cells. Hence a resistance to 6-
mercaptopurine due to MRP4 overexpression (Peng et al
2008) or to cyclic nucleotides in cells characterized by
MRP8 overexpression (Guo et al 2009), may have a similar
denominator (a polar nucleotide which cannot efflux out
of the cell), but does not explain the differences found
between e.g. ara-C and gemcitabine, which is based on
metabolism, an aspect not covered earlier in literature.
In conclusion, we have demonstrated that the ABC trans-
porters MRP4 and MRP5 may play a role in nucleoside re-
sistance by effluxing the monophosphate. This resistance
may be bypassed by prolonged exposure.Abbreviations
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